Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
74,286,796
-
Shares change
-
-6,464,264
-
Total reported value, excl. options
-
$103,280,736
-
Value change
-
-$10,483,186
-
Put/Call ratio
-
28%
-
Number of buys
-
50
-
Number of sells
-
-98
-
Price
-
$1.39
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2023
203 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74,286,796 shares
of 207,440,936 outstanding shares and own 36% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (13,139,556 shares), ARMISTICE CAPITAL, LLC (9,193,000 shares), Point72 Asset Management, L.P. (4,975,000 shares), Meditor Group Ltd (4,402,973 shares), VANGUARD GROUP INC (4,263,265 shares), Bellevue Group AG (4,208,264 shares), PLATINUM INVESTMENT MANAGEMENT LTD (3,469,634 shares), MILLENNIUM MANAGEMENT LLC (3,346,726 shares), Two Seas Capital LP (2,941,872 shares), and Parkman Healthcare Partners LLC (2,132,309 shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.